Search Results for "indomethacin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for indomethacin. Results 1 to 4 of 4 total matches.
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
of symptoms
No evidence that indomethacin, a traditional
choice, is more effective than other NSAIDs
Can ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
NSAIDs.15 The
potent NSAID indomethacin is associated with a
high risk of GI adverse effects; it should ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
that indomethacin (Indocin,
and others), a traditional choice that has a relatively
high incidence of adverse ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
anti-inflammatory
drug (NSAID) indomethacin, which inhibits pancreatic
release of glucagon ...
The FDA has approved dasiglucagon (Zegalogue –
Zealand) for subcutaneous (SC) treatment of severe
hypoglycemia in patients ≥6 years old with diabetes.
Dasiglucagon is the third glucagon product to be
marketed in the US that does not require reconstitution
before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi,
an intranasal powder approved for use in patients
≥4 years old, have been available since 2019.
Injectable glucagon emergency kits (GlucaGen
HypoKit, and generics) have been available for years,
but they require...